key: cord-0259589-a9docix7 authors: Benschop, R. J.; Tuttle, J. L.; Zhang, L.; Poorbaugh, J.; Kallewaard, N. L.; Vaillancourt, P.; Crisp, M. L.; Trinh, T. N. V.; Freitas, J. J.; Beasley, S.; Daniels, M.; Haustrup, N.; Higgs, R. E.; Nirula, A.; Cohen, M. S.; Marovich, M. title: The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination date: 2021-12-16 journal: nan DOI: 10.1101/2021.12.15.21267605 sha: cad6a9f533360d76571e2aef9d006099479884c0 doc_id: 259589 cord_uid: a9docix7 As the COVID-19 pandemic evolves, and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of SARS-CoV-2 infection are also accelerating. This longitudinal serological study evaluated the magnitude and potency of the endogenous antibody response to COVID-19 vaccination in participants who first received a COVID-19 monoclonal antibody in a prevention study. Over the course of six months, serum samples were collected from the prevention population (nursing home residents and staff) enrolled in the BLAZE-2 clinical trial who had received either bamlanivimab (4200 mg) or placebo. In an unplanned component of this trial, a subset of these participants was subsequently fully vaccinated with two doses of either SpikeVax (Moderna) or Comirnaty (BioNTech/Pfizer) COVID-19 mRNA vaccines, as part of the US vaccination program. This post-hoc analysis assessed the immune response to vaccination for the subset of participants (N=135) without prior SARS-CoV-2 infection. Antibody titers and potency were assessed using three assays against SARS-CoV-2 proteins that bamlanivimab does not significantly bind to, thereby reflecting the endogenous antibody response. All bamlanivimab and placebo participants mounted a robust immune response to full COVID-19 vaccination, irrespective of age, risk-category and vaccine type, with any observed differences unlikely to be clinically meaningful. These findings are pertinent for informing public health policy with results that suggest a complementary role for COVID-19 monoclonal antibodies (mAbs) with COVID-19 vaccines and that the benefit of receiving COVID-19 vaccination at the earliest opportunity outweighs the minimal effect on the endogenous immune response due to prior prophylactic COVID-19 mAb infusion. In response to the coronavirus disease 2019 (COVID-19) pandemic, many prophylactic and therapeutic treatments were rapidly developed to target the highly pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1, 2) . Antibodies that target the Receptor Binding Domain (RBD) of the spike protein of SARS-CoV-2 are essential for protection against COVID-19 disease (3, 4) , as these antibodies reduce SARS-CoV-2 viral load, which is correlated with disease severity (5) (6) (7) . Active immunity against COVID-19 disease develops when endogenous RBD-neutralizing antibodies are elicited following exposure to a pathogenic agent, such as SARS-CoV-2 or a COVID-19 vaccine (3, 4) ; and passive immunity is conferred through the administration of exogenous antibodies, such as mAbs, that precisely target and bind to the RBD. Several authorized clinically active COVID-19 mAbs provide immediate protective immunity that persists for as long as the antibody concentration exceeds that required for neutralization of the virus (8) (9) (10) (11) (12) . Bamlanivimab was the first COVID-19 mAb to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and Drug Administration (FDA), but was later revoked in April 2021, due to the increase of SARS-CoV-2 viral variants that were resistant to bamlanivimab alone (11, 13) . Vaccine-induced protection develops over time, often requiring multiple doses but offers clear advantages by eliciting a broader polyclonal immune response and establishing immunological memory for durable immunity (14, 15) . There are currently insufficient safety and efficacy data with COVID-19 vaccines in individuals who have previously received COVID-19 mAbs; in the absence of data both the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) recommend the deferral of vaccination for 90 days following mAb treatment and more recently, if mAbs were received for post-exposure prophylaxis (PEP), CDC now recommends vaccine deferral for 30 days (16, 17) . In order to avoid unnecessary delays for individuals seeking The BLAZE-2 (NCT04497987) clinical trial was a phase 3, randomized, double-blind, placebo-controlled, single-dose study to evaluate whether bamlanivimab prevents SARS-CoV- Table 1 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12. 15.21267605 doi: medRxiv preprint The median age of staff participants (N=99) was 43 years compared with resident participants (N=36) who had a median age of 72 years. Of the 99 staff participants, 6% were 65 years or older. A total of 81 participants (60%) met the criteria for high-risk of developing severe COVID-19 disease, which included 100% of the residents and 45% of the staff. The criteria for classifying high-risk of severe COVID-19 disease for this post-hoc analysis have been described previously (13) . High-risk categorization criteria (13) Robust endogenous antibody response to full COVID-19 vaccination following anti-SARS- A multiplex custom assay was performed on serum samples obtained from fully vaccinated participants (N=135) to measure the magnitude of the binding antibody response. The assay was performed against the spike-RBD carrying the E484Q alteration (spike-RBD-E484Q) and the spike N-terminal domain (spike-NTD) ( Table 2 ). Since the epitope for bamlanivimab lies . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.15.21267605 doi: medRxiv preprint within the spike RBD (27, 28) and bamlanivimab does not significantly bind to the RBD with alterations at residue E484 (29, 30) or to NTD, antibody titers against these two SARS-CoV-2 proteins reflect the endogenous antibody response. Compared with placebo, treatment with bamlanivimab resulted in a 1.8-fold (p=0.001) and 2.0-fold (p<0.001) lower titer against spike-RBD-E484Q and spike-NTD, respectively (least square means comparison) (Fig. 1) . Fig. 1 : Binding antibody titers against (a) Spike-RBD-E484Q and (b) Spike-NTD for participants who had received either bamlanivimab or placebo infusion and were subsequently fully vaccinated (SpikeVax or Comirnaty) against COVID-19. Antibody titers were rescaled after adjusting for covariates. Boxes and horizontal bars denote the interquartile range (IQR) and the median, respectively. Length of whiskers corresponds to 1.5 times the IQR. These binding antibody titer data were grouped into participants who were either staff or residents (Fig. 2a) and participants who received either SpikeVax or Comirnaty (Fig. 2b) , to ascertain firstly, whether the immune response to full vaccination differs between these two groups and secondly, whether bamlanivimab infusion disparately affected these groups. Antibody titers from staff (median age 43 years) were 2.7 and 2.3 times (p<0.001) higher than titers from residents (median age 72 years) against Spike-RBD-E484Q and spike-NTD, respectively (Fig 2a) . The effect of bamlanivimab on vaccine-induced antibody titer against Spike-RBD-E484Q and spike-NTD (p=0.388 and p=0.105, respectively) was similar for both . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.15.21267605 doi: medRxiv preprint residents and staff (Fig. 2a) . There was no significant difference between antibody titers for participants who received SpikeVax or Comirnaty against either Spike-RBD-E484Q or spike-NTD (p=0.722 and p=0.397, respectively) (Fig. 2b) . For participants who received either vaccine, the effect of bamlanivimab on the vaccine-induced antibody titer against Spike-RBD-E484Q and spike-NTD was also not significantly different (p=0.922 and p=0.756, respectively). These same trends were also observed for antibody titers measured against the SARS-CoV-2 beta variant (B.1.351), which is not recognized by bamlanivimab ( fig. S1 ). Binding antibody titers against Spike-RBD-E484Q and spike-NTD comparing samples from fully vaccinated participants who were (a) staff or resident (top) and further grouped by those who received placebo or bamlanivimab prior to vaccination (bottom) (b) participants who received SpikeVax or Comirnaty vaccine (top) and further grouped by those who received placebo or bamlanivimab prior to vaccination (bottom). Antibody titers were rescaled after adjusting for covariates. Boxes and horizontal bars denote the interquartile range (IQR) and the median, respectively. Length of whiskers corresponds to 1.5 times the IQR. Since the staff (N=99) included participants who were at high-risk of developing severe COVID-19 disease, antibody titers were also compared between high-risk staff (N=45) with is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The potency of the endogenous antibodies produced in response to full vaccination was evaluated in two ways: based on angiotensin-converting enzyme 2 (ACE2) binding inhibition measured with the custom multiplex assay and pseudovirus neutralization activity using a vesicular stomatitis (VSV)-based pseudovirus. The ACE2 binding inhibition potency expresses how effectively the endogenous antibodies inhibited RBD-(E484Q)-ACE2 binding. Compared with placebo, receipt of bamlanivimab resulted in a 4.1-fold (p<0.001) lowering in ability of the endogenous antibody response to inhibit ACE2 binding (Fig. 3a) . These ACE2 binding inhibition potency data were grouped into participants who were either staff or residents (Fig. 3b ) and participants who received either SpikeVax or Comirnaty (Fig. 3c) , to ascertain firstly, whether the potency of antibodies elicited following full vaccination differs between these groups and secondly, whether bamlanivimab infusion prior to full vaccination disparately affects these groups. who were staff or resident (top) and further grouped by those who received placebo or bamlanivimab (bottom) (c) who received Comirnaty or SpikeVax (top) and further grouped by those who received placebo or bamlanivimab (bottom). ACE2 binding inhibition potency measured as 1/IC50 and adjusted for covariates. Boxes and horizontal bars denote the interquartile range (IQR) and the median reciprocal IC50, respectively. Length of whiskers corresponds to 1.5 times the IQR. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The ACE2 binding inhibition potency of endogenous antibodies was measured as 2.5 times (p<0.001) higher for staff than for residents (Fig. 3b) . There was no disparity in ACE2 binding inhibition potency between participants who received SpikeVax or Comirnaty (p=0.162) (Fig. 3c ). The magnitude of the bamlanivimab effect on ACE2 binding inhibition potency was similar for both resident and staff (p=0.233) (Fig. 3b ) and for participants who had SpikeVax or Comirnaty (p=0.574) (Fig. 3c) . We observed no difference in ACE2 binding inhibition potency between non-high-risk and high-risk staff (p=0.441), nor was the magnitude of the bamlanivimab effect on ACE2 binding inhibition potency different for these groups (p=0.084) To assess the functional polyclonal antibody response against the full-length spike, neutralization potency was measured using a VSV-based pseudovirus for samples from a subset of participants (N=49; 21 placebo, 28 bamlanivimab). The participants sampled had all received their first vaccine dose 64 days or fewer (median 57 days) after a bamlanivimab or placebo infusion and thereby were the most likely to exhibit an effect of bamlanivimab infusion on the immune response to subsequent vaccination. There was no statistically significant difference in pseudovirus neutralization potency against Spike-E484Q for participants who received either placebo or bamlanivimab (p=0.078) (Fig. 4) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint To corroborate the results obtained using different assays to measure the antibody titers, ACE2 binding inhibition potency and pseudoviral neutralization potency, the correlation strength was determined between all assay results against Spike-RBD-E484Q for the subset of 114 samples from 49 participants. A high degree of correlation was observed between all assay results (Fig. 5 ). The Spearman correlation, ρ, was determined as 0.87 (p<0.001) for ACE2 binding inhibition data with pseudovirus neutralization data. Similarly, highly significant correlations were observed between pseudovirus neutralization data and antibody titers (ρ =0.84, p<0.001) and between ACE2 binding inhibition data and antibody titers (ρ =0.91, p<0.001). These strong correlations also extended to data from participants who received either bamlanivimab or placebo (Fig. 5 ). . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (19.8-192 .6 µg/mL). While the study did not allow for conclusions to be drawn about the immune response to the first vaccine dose, the data demonstrate that at no point in time did the groups divert beyond the small difference in titer observed at full vaccination. Additionally, there are no obvious differences between the immune responses shown in the three panels (Fig. 6) . These trends were also observed for longitudinal antibody titers against the spike-NTD ( fig. S5 ). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint In this post-hoc analysis of the BLAZE-2 nursing home study, all participants demonstrated a robust immune response to full COVID-19 vaccination, regardless of preceding bamlanivimab or placebo infusion and irrespective of age, risk-category and vaccine type, with any observed differences unlikely to be clinically relevant. Furthermore¸ the interval between mAb infusion and COVID-19 vaccination did not affect this conclusion. These are significant findings in the pursuit of informed treatment planning, particularly for individuals at high risk for severe disease, and would support earlier COVID-19 vaccination for individuals who are currently deferring following mAb receipt, as per current CDC and WHO guidelines (16, 17) . Here, we demonstrate that SARS-CoV-2-naïve individuals who have received a prophylactic mAb can still mount a robust immune response to COVID-19 vaccination and therefore the benefit of prompt COVID-19 vaccination outweighs the minimal effect of a prior prophylactic COVID-19 mAb. The immune response of participants to COVID-19 vaccination was evaluated using assays to measure the antibody titers, ACE2 binding inhibition and pseudoviral neutralization. There was a high degree of correlation between all assay results, suggesting reliable trends that demonstrated minimal differences in immune response to COVID-19 vaccination for participants who previously received either bamlanivimab or placebo. Notably, assays were measured against multiple domains of the spike protein that bamlanivimab does not significantly bind to, thereby reflecting the endogenous antibody response and with consistently strong correlations. Growing evidence indicates that binding and neutralizing antibodies correlate with COVID-19 vaccine efficacy as many researchers endeavor to identify immune correlates of protection (4, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 18, 19) . A recent modelling study identified a strong non-linear relationship between mean neutralization level and the reported protection of vaccines and predicted that the 50% protective neutralization level of a COVID-19 vaccine was achieved at approximately 20% of the mean convalescent titer (31) . Another study also estimated vaccine efficacy based on antibody marker level and showed that a 10-fold lower antibody titer for SpikeVax vaccine recipients, only reduced vaccine efficacy from 96.1% to 90.7% (18) . In our study antibody titers for fully vaccinated participants who had previously received bamlanivimab compared with placebo were reduced by 2-fold or less. Therefore, despite some differences reaching statistical significance, it is unlikely that a titer difference of this magnitude translates to clinically relevant interference. Higher antibody titers in individuals who were fully vaccinated with SpikeVax compared with Comirnaty have been reported (32) , yet each vaccine has demonstrated more than 90% efficacy in preventing COVID-19 illness (33, 34) . We concluded here that there was no significant difference in the antibody response to different mRNA COVID-19 vaccines and that bamlanivimab infusion also did not disparately affect participants who had either vaccine. Understanding the endogenous antibody responses to COVID-19 vaccines is particularly important for older and immunocompromised individuals, who are at high-risk of developing severe COVID-19 and have therefore been the targeted recipients of prophylactic and treatment mAbs (35) (36) (37) (38) . The participants in this study included both residents and staff of US skilled nursing and assisted living facilities, allowing us to evaluate any impact of age and risk categorization on the vaccine-induced antibody response following receipt of prophylactic bamlanivimab or placebo. Firstly, staff (median age 43 years) were shown to have significantly higher antibody titers and greater antibody potency than residents (median age 72 years), which is consistent with the literature that has shown stronger immune responses in younger individuals (39) . Secondly, bamlanivimab had a similar effect on the antibody titers and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.15.21267605 doi: medRxiv preprint potency in both residents and staff, which informs that bamlanivimab did not disparately affect the immune response to full COVID-19 vaccination of participants of different ages. An additional sub-analysis was completed for the staff who were dichotomized into non-high-risk and high-risk participants based on pre-determined risk factors for developing severe COVID-19 disease (13) . Since only 13% of the high-risk staff were 65 years or older, the comparative differences between these risk groups were largely attributable to factors other than older age. Firstly, no differences in antibody titer or potency were observed between the two risk-groups, and bamlanivimab infusion also did not disparately affect the titers and potency of elicited antibodies in participants of different risk categorization. These results therefore demonstrate that participants can mount a strong immune response to COVID-19 vaccination following a mAb infusion, irrespective of age and high-risk categorization. This is an important finding as mAbs have been granted EUAs primarily for the treatment of individuals who are at high risk of developing severe COVID-19 and the current lack of data resulted in substantial delays between COVID-19 mAb and vaccination for this group. A further consideration based on the reduced protective efficacy of COVID-19 vaccines over time and against certain SARS-CoV-2 variants, additional doses are increasingly administered to boost the immune response, with high-risk individuals being prioritized (40) . Taken together, these data reinforce the conclusions, that individuals who have previously received a COVID-19 mAb can proceed with COVID-19 vaccination and mount a strong immune response, which could be further boosted by additional vaccine doses, as per the latest clinical guidance. The vaccine-induced antibody potency was also evaluated using an ACE2 binding inhibition assay and a pseudovirus neutralization assay with closely correlated results. There was no significant difference in pseudovirus neutralization potency between individuals who received either bamlanivimab or placebo, however a significantly lower ACE2 binding inhibition potency was detected. The contrast in measured antibody potency is likely explained by the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.15.21267605 doi: medRxiv preprint breadth of epitope assessed in each assay; the ACE2 binding inhibition assay assesses RBDbinding antibodies only, whereas the pseudovirus assay assesses the functionality of the polyclonal antibody response against the full-length spike (see minimum significant ratio in Materials and Methods for full description). The strong correlation between the potency assays and overall high levels of neutralizing activity suggests minimal impact on immune protection conferred by COVID-19 vaccination, regardless of prior bamlanivimab or placebo infusion. Previous studies investigating immune evasion have determined that complete loss of antibody neutralizing activity against SARS-CoV-2 variants corresponded to a greater than 40-fold change reduction compared with neutralizing activity against wild type (WT) pseudovirus (41, 42) . Therefore, the decrement in antibody titers observed in participants who received prior bamlanivimab infusion compared with placebo is unlikely to be clinically meaningful. This study has several limitations; First, this analysis was not a pre-planned component of the BLAZE-2 trial and therefore vaccine type and timing were determined by circumstance. Consequently, the post-hoc analysis population was determined as described in the Materials and Methods and therefore the data presented are limited by the sample size and demographics. A total of 499 samples from fully vaccinated participants who met the inclusion criteria were assessed for antibody titer and ACE2 binding inhibition potency using a custom Luminexbased assay. Owing to the custom nature of this assay, it was decided to perform a standard pseudovirus neutralization assay to complement and corroborate these data. Due to logistical limitations, purposive sampling was used to select samples for the pseudovirus assay from a subset of participants (N=49) who received their first vaccine within 64 days of either bamlanivimab or placebo. This group of participants were selected as they represented those most likely to exhibit an effect of bamlanivimab on pseudovirus neutralization potency. Despite the smaller sample, the neutralization potency against Spike-RBD-E484Q and the beta variant is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint This analysis only assessed the impact of a single mAb on the endogenous immune response to a COVID-19 vaccine, however, we hypothesize similar results for other mAbs that reduce viral load upon administration (43) . This study is also limited to participants who received an mRNA vaccine; therefore, it is not known whether these findings extend to other vaccine types. This analysis also did not assess the simultaneous administration of vaccine and mAb, however we have recently shown that patients with mild or moderate COVID-19 that were administered bamlanivimab or bamlanivimab and etesevimab together early in infection elicited a wide breadth of antigenic responses to SARS-CoV-2 (44). Since COVID-19 vaccination was an unplanned component of the BLAZE-2 trial, the temporal variability of vaccination dosing relative to the serum sampling visits had to be accounted for throughout this post-hoc analysis. The most appropriate way to compare the immune responses of participants to vaccination was to adjust the data of each participant for two covariates (Materials and Methods). Longitudinal titer data without covariate adjustment were also visualized by arranging participants into three groups based on the interval between bamlanivimab or placebo infusion and first vaccine dose. Although this study did not allow for conclusions to be drawn about the immune response to the first dose of vaccine, the longitudinal titer data did not deviate beyond the small difference in titer observed at full vaccination. Whilst this approach was limited by the number of participants who could be included in each group, there were no obvious differences in the antibody responses between the three groups, which notably included 97 participants (70%) who had received the first vaccine dose within 90 days of bamlanivimab or placebo infusion (16, 17) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The BLAZE-2 trial was a phase 3, randomized, double-blind, placebo-controlled, single-dose SARS-CoV-2 prevention study and has been described previously (22) . Participants of the BLAZE-2 study included residents and staff of US skilled nursing and assisted living facilities who were randomized to the study drug, bamlanivimab (4,200 mg) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.15.21267605 doi: medRxiv preprint infusion and (d) had at least one serum sample obtained more than 2 weeks following the second vaccine dose. The CDC describes an individual as fully vaccinated after 2 weeks following the second COVID-19 vaccine doses in a 2-dose series, such as for Comirnaty or SpikeVax (23). The baseline characteristics for the 135 participants who met these criteria and were included in this post-hoc analysis are presented in Table 1 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.15.21267605 doi: medRxiv preprint following the recommended period specified in the EUA factsheet for each vaccine (21 and 28 days later for Comirnaty and SpikeVax, respectively) (25, 26) . To evaluate the effect of bamlanivimab infusion on the subsequent antibody response to full COVID-19 vaccination, the following criteria were adopted to select samples from the 135 participants for statistical analysis: (a) exclude participant samples that were obtained prior to the receipt of the second vaccine dose; (b) exclude samples from participants who did not have a record of a second vaccine dose at the time of the analysis; (c) exclude samples which were obtained within 14 days of the second vaccine dose (i.e. only use samples collected after full vaccination, as determined by the CDC (23); (d) If more than one sample was obtained after a participant was fully vaccinated, the lattermost sample was selected for analysis. The serum sampling period was pre-specified in the BLAZE-2 protocol and the final serum samples were collected on day 169 (22) . A total of 499 samples from 135 participants met these criteria and assays were performed to measure antibody titers and ACE2-RBD binding inhibition as described in subsequent sections. Prior to use in each assay, serum samples were centrifuged for 5 minutes at 10000 x g to pellet any debris. Since the ACE2-RBD binding inhibition results were collected using a custom Luminex-based assay, a standard VSV pseudoviral assay was also performed to complement and corroborate these data. Owing to the substantial number of serum samples collected, the pseudoviral assay was performed on a purposive sample of 74 samples from 49 fully vaccinated participants (Fig. 7 ). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.15.21267605 doi: medRxiv preprint placebo and the subsequent receipt of the first COVID-19 vaccination dose, T1. Each of the 135 participants were placed into one of the three groups: T1≤64 days, 64